Overview

LipAD™ - Proprietary Lipid-Assembled Drug Delivery Platforms 

Career_Benefit.png

TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties.

TLC has proprietary solution for pharmaceutical product development called LipAD™. LipAD™ allows the design of medicines at the nanometer scale, improving drug solubility, protecting molecules from degradation, or targeting drug delivery to specific tissues and compartments within a cell, creating drugs that are longer lasting with increased efficacy, and enabling new mechanisms that would otherwise be impractical.

These lipid-based technologies enable straightforward development of new formulations of well-known drugs by improving upon their clinical characteristics.

Prolonging Duration of Effect: BioSeizer®Technology

Many different types of drugs are quickly metabolized and removed from circulation, limiting the duration of their effect following a single dose. Frequent dosing may compensate for a short duration of effect, but this is not always a good solution. Frequent dosing of drugs delivered by injection can be inconvenient, painful and carries an increased risk of infection.

Our proprietary BioSeizer® technology entraps drugs to control the rate at which a therapeutic molecule is released from a lipid nanoparticle once in the body. BioSeizer® nanoparticles consist of a drug wrapped within multiple layers of lipid membrane, precisely designed to release the drug at a constant rate as each layer collapses over time. This technology can be applied to a wide range of molecular payloads, including biologics, small molecules and oligonucleotides. Our technology for sustained release has advantages in many applications.

We are developing several new therapies using BioSeizer®, including TLC599 for osteoarthritis, TLC399 for the treatment of eye diseases, and TLC590 for postsurgical pain.

More on BioSeizer®
Micrograph